2 Hot Biotech IPOs to Consider

Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be. In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy. Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone.